Trending at Lumira Ventures

FDA Grants G1 Therapeutics Breakthrough Therapy Designation & Provides Q2 2019 Financial Update

Jennifer Schram Portfolio News, G1 Therapeutics

Related Article: G1 Therapeutics Provides First Quarter 2019 Corporate and Financial Update RESEARCH TRIANGLE PARK, N.C., Aug. 07, 2019 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today provided a corporate and financial update for the second quarter ended June 30, 2019. …

Phase 2 Trial Data Demonstrates Longer Survival Rates for Women with Metastatic Breast Cancer Receiving Trilaciclib & Chemotherapy

Jennifer Schram Portfolio News, G1 Therapeutics

– Detailed data from this trial will be presented at a medical meeting later this year – RESEARCH TRIANGLE PARK, N.C., June 18, 2019 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq: GTHX), a clinical-stage oncology company, today announced preliminary overall survival (OS) results from …

G1 Therapeutics to Report Myelopreservation Data from Randomized Phase 2 Trial of Trilaciclib/Chemotherapy/Tecentriq® in Small Cell Lung Cancer in Fourth Quarter 2018

jacki jenuth Portfolio News, G1 Therapeutics

G1 Therapeutics (Nasdaq: GTHX), a clinical-stage oncology company, today announced that it is expediting analyses of myelopreservation data from its randomized Phase 2 trial of trilaciclib in combination with chemotherapy and Tecentriq® (atezolizumab) in first-line small cell lung cancer (SCLC). Myelopreservation results …

G1 Therapeutics Expands Executive Leadership Team with Appointment of John Demaree as Chief Commercial Officer and Stillman Hanson as General Counsel

jacki jenuth Portfolio News, G1 Therapeutics

RESEARCH TRIANGLE PARK, N.C., July 09, 2018 (GLOBE NEWSWIRE) — G1 Therapeutics, Inc. (Nasdaq:GTHX), a clinical-stage oncology company, today announced appointments for two newly created executive leadership roles to support the company’s continued growth. John Demaree joins the company as …

G1 Therapeutics Announces Positive Trilaciclib Phase 2a Topline Data Showing Robust Myelopreservation Benefits in Patients with Small Cell Lung Cancer

jacki jenuth Portfolio News, G1 Therapeutics

Statistically significant results highlight benefit of trilaciclib in several prospectively-defined parameters, including: Grade 4 neutropenia, G-CSF usage, and chemotherapy dose reductions and delays Clinically meaningful data favoring trilaciclib versus placebo, including: febrile neutropenia, Grade 3/4 anemia, and red blood cell …